The trogarzo market research report is one of a series of new reports that provides trogarzo market statistics, including the trogarzo industry global market size, regional shares, competitors with the trogarzo market share, detailed trogarzo market segments, market trends, and opportunities, and any further data you may need to thrive in the trogarzo industry. This trogarzo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to growing adoption of monoclonal antibody therapies, increasing awareness of drug resistance, rising healthcare infrastructure, expansion of telehealth services, rising demand for long-term management solutions. Major trends in the forecast period include advancements in monoclonal antibody therapies, expanding research and development, advancements in virology research, development of innovative injectable formulations, advancements in clinical research.
The increasing prevalence of HIV or AIDS is expected to drive the growth of the trogarzo market. HIV (Human Immunodeficiency Virus) is a viral infection that weakens the immune system and, if left untreated, can progress to AIDS (Acquired Immune Deficiency Syndrome), the most severe stage of the disease. The spread of HIV or AIDS is influenced by factors such as limited access to healthcare, lack of education and awareness, migration, urbanization, and various socioeconomic conditions. Trogarzo provides an effective solution for patients with multidrug-resistant HIV by preventing the virus from infecting immune cells, leading to better viral suppression and significantly improved patient health. For example, according to the Joint United Nations Programme on HIV/AIDS, approximately 39.9 million people were living with HIV globally in 2023, with 1.3 million new infections and 630,000 AIDS-related deaths. This growing prevalence is contributing to the expansion of the trogarzo market.
A significant trend in the trogarzo market is the introduction of an intramuscular (IM) administration formulation to make treatment easier and more convenient for heavily treatment-experienced adults with multidrug-resistant HIV. The IM method delivers the medication directly into the muscle, enabling faster absorption and simplifying the treatment process. For instance, in January 2024, Theratechnologies Inc., a Canadian pharmaceutical company, submitted a supplemental biologics license application (sBLA) for an IM version of Trogarzo (ibalizumab-uiyk). This formulation is intended for heavily treatment-experienced adults with HIV-1 infection. The proposed IM method aims to streamline the treatment regimen by allowing a rapid injection every two weeks, complementing the recently FDA-approved 2,000-mg intravenous (IV) push loading dose, which can be administered in just 90 seconds.
In March 2024, TaiMed Biologics, a Taiwan-based biotechnology company that manufactures Trogarzo, partnered with AcedrA BioPharmaceuticals to expand the drug’s availability in the Middle East and North Africa (MENA) region. This partnership seeks to address unmet medical needs and increase access to treatment for heavily treatment-experienced HIV patients who have limited options. AcedrA BioPharmaceuticals, based in Saudi Arabia, provides scientific and business services throughout the Middle East and Africa region.
The key company operating in the trogarzo market is TaiMed Biologics Inc.
North America was the largest region in the trogarzo market in 2024. The regions covered in trogarzo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the trogarzo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Trogarzo is a monoclonal antibody used to treat multidrug-resistant HIV-1 in patients who have not responded to other antiretroviral therapies. It is indicated for use in combination with other antiretroviral drugs for patients with multidrug-resistant (MDR) HIV-1 who have limited or no effective treatment options.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary clinical indications for Trogarzo include multidrug-resistant HIV-1 infection, treatment-experienced HIV-1 patients, co-infected HIV-1 patients, and the prevention of HIV-1 resistance. Multidrug-resistant HIV-1 refers to cases where the virus is resistant to several antiretrovirals, and Trogarzo offers a unique mechanism of action as an alternative treatment. It is distributed through various channels such as hospitals, clinics, retail, and specialty pharmacies, and is used by a wide range of patients, including adults and the elderly.
The trogarzo market consists of sales of combination therapy, and single-dose intravenous (IV) infusion. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to growing adoption of monoclonal antibody therapies, increasing awareness of drug resistance, rising healthcare infrastructure, expansion of telehealth services, rising demand for long-term management solutions. Major trends in the forecast period include advancements in monoclonal antibody therapies, expanding research and development, advancements in virology research, development of innovative injectable formulations, advancements in clinical research.
The increasing prevalence of HIV or AIDS is expected to drive the growth of the trogarzo market. HIV (Human Immunodeficiency Virus) is a viral infection that weakens the immune system and, if left untreated, can progress to AIDS (Acquired Immune Deficiency Syndrome), the most severe stage of the disease. The spread of HIV or AIDS is influenced by factors such as limited access to healthcare, lack of education and awareness, migration, urbanization, and various socioeconomic conditions. Trogarzo provides an effective solution for patients with multidrug-resistant HIV by preventing the virus from infecting immune cells, leading to better viral suppression and significantly improved patient health. For example, according to the Joint United Nations Programme on HIV/AIDS, approximately 39.9 million people were living with HIV globally in 2023, with 1.3 million new infections and 630,000 AIDS-related deaths. This growing prevalence is contributing to the expansion of the trogarzo market.
A significant trend in the trogarzo market is the introduction of an intramuscular (IM) administration formulation to make treatment easier and more convenient for heavily treatment-experienced adults with multidrug-resistant HIV. The IM method delivers the medication directly into the muscle, enabling faster absorption and simplifying the treatment process. For instance, in January 2024, Theratechnologies Inc., a Canadian pharmaceutical company, submitted a supplemental biologics license application (sBLA) for an IM version of Trogarzo (ibalizumab-uiyk). This formulation is intended for heavily treatment-experienced adults with HIV-1 infection. The proposed IM method aims to streamline the treatment regimen by allowing a rapid injection every two weeks, complementing the recently FDA-approved 2,000-mg intravenous (IV) push loading dose, which can be administered in just 90 seconds.
In March 2024, TaiMed Biologics, a Taiwan-based biotechnology company that manufactures Trogarzo, partnered with AcedrA BioPharmaceuticals to expand the drug’s availability in the Middle East and North Africa (MENA) region. This partnership seeks to address unmet medical needs and increase access to treatment for heavily treatment-experienced HIV patients who have limited options. AcedrA BioPharmaceuticals, based in Saudi Arabia, provides scientific and business services throughout the Middle East and Africa region.
The key company operating in the trogarzo market is TaiMed Biologics Inc.
North America was the largest region in the trogarzo market in 2024. The regions covered in trogarzo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the trogarzo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Trogarzo is a monoclonal antibody used to treat multidrug-resistant HIV-1 in patients who have not responded to other antiretroviral therapies. It is indicated for use in combination with other antiretroviral drugs for patients with multidrug-resistant (MDR) HIV-1 who have limited or no effective treatment options.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary clinical indications for Trogarzo include multidrug-resistant HIV-1 infection, treatment-experienced HIV-1 patients, co-infected HIV-1 patients, and the prevention of HIV-1 resistance. Multidrug-resistant HIV-1 refers to cases where the virus is resistant to several antiretrovirals, and Trogarzo offers a unique mechanism of action as an alternative treatment. It is distributed through various channels such as hospitals, clinics, retail, and specialty pharmacies, and is used by a wide range of patients, including adults and the elderly.
The trogarzo market consists of sales of combination therapy, and single-dose intravenous (IV) infusion. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Trogarzo Market Characteristics4. Trogarzo Market Trends And Strategies5. Trogarzo Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Trogarzo Pricing Analysis & Forecasts30. Global Trogarzo Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Trogarzo Market32. Recent Developments In The Trogarzo Market
3. Trogarzo Market Biologic Drug Characteristics
6. Global Trogarzo Growth Analysis And Strategic Analysis Framework
8. Trogarzo Market Segmentation
9. Global Trogarzo Epidemiology Of Clinical Indications
10. Trogarzo Market Regional And Country Analysis
11. Asia-Pacific Trogarzo Market
12. China Trogarzo Market
13. India Trogarzo Market
14. Japan Trogarzo Market
15. Australia Trogarzo Market
16. South Korea Trogarzo Market
17. Western Europe Trogarzo Market
18. UK Trogarzo Market
19. Germany Trogarzo Market
20. France Trogarzo Market
21. Eastern Europe Trogarzo Market
22. North America Trogarzo Market
23. USA Trogarzo Market
24. Canada Trogarzo Market
25. South America Trogarzo Market
26. Middle East Trogarzo Market
27. Africa Trogarzo Market
28. Trogarzo Market Competitive Landscape And Company Profiles
29. Global Trogarzo Market Pipeline Analysis
33. Trogarzo Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Trogarzo Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on trogarzo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for trogarzo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The trogarzo market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Clinical Indication: Human Immunodeficiency Virus-1 Infection Multidrug-Resistant; Human Immunodeficiency Virus-1 Infection Treatment-Experienced; Human Immunodeficiency Virus-1 Infection Co-infected Patients; Prevention Of Human Immunodeficiency Virus-1 Resistance2) By Distribution Channel: Hospital And Clinics; Retail And Specialty Pharmacies
3) By End-User: Adult Patients; Geriatric Patients
Key Companies Profiled: TaiMed Biologics Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- TaiMed Biologics Inc.